Drug Trial Radar · NCT03664180
Comparison of Anticoagulation Prolongation vs. no Anticoagulation in STEMI Patients After Primary PCI
Last checked: Nov 20, 2026Latest source record: May 3, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
2,989
Actual
Start
Jan 11, 2019
Primary completion
Nov 23, 2022
Study completion Nov 23, 2022
Sponsor
- Lead sponsor
- Beijing Anzhen HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Chinese Academy of Medical Sciences, Fuwai Hospital; Groupe Hospitalier Pitie-Salpetriere
- First posted
- Sep 10, 2018
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Triple (participant, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The RIGHT study is a large randomized study dedicated to post-PPCI anticoagulation in STEMI patients. The investigators propose to evaluate the clinical efficacy and safety of anticoagulation prolonged for at least 48 hours after the procedure vs. no prolongation of anticoagulation after procedure in patients with STEMI treated with bivalirudin during PPCI (primary hypothesis). When allocated to anticoagulation prolongation by randomization, the subject will be assigned to UFH, enoxaparin or bivalirudin (same regimen allocated by centre) for at least 48 hours after PPCI. The results from this study are expected to provide guidance on the risk/benefit of post-procedural anticoagulation in patients with STEMI.
Conditions
- STEMI - ST Elevation Myocardial Infarction
Interventions
BivalirudinDrug
IV infusion of 0.2 mg/kg/h (low-rate infusion) for at least 48h after the procedure or until discharge from CCU if it occurs later
EnoxaparinDrug
40mg/d s.c.for at least 48h after the procedure or until discharge from CCU if it occurs later
Unfractionated heparinDrug
IV infusion of 10 U/kg/h (maximum 1000 U) initially, adjusted to maintain ACT between 150 and 220 seconds for at least 48h after the procedure or until discharge from CCU if it occurs later
Bivalirudin placeboDrug
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later
Enoxaparin placebo syringeDrug
Placebo syringe will be only prepared by a designated unblended medical professional on site. Placebo syringe will be presented in identical containers as a clear, colorless, sterile liquid of saline.Subcutaneous injection once a day for at least 48 hours after the procedure or until discharge from CCU if it occurs later.
Unfractionated heparin placeboDrug
Matching placebo IV infusion for at least 48h after the procedure or until discharge from CCU if it occurs later.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Primary efficacy endpoint - number of event of a composite of all-cause death, non-fatal myocardial infarction, non-fatal stroke, stent thrombosis (definite) or urgent revascularization (any vessel)Time frame: 30 days
- Primary safety endpoint - The number of event of major bleedingTime frame: 30 days
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Beijing Anzhen Hospital, Capital Medical University
Beijing, China
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.